Expertise and opinions of authors published by ForbesBooks. Imprint operated under license. In my last article, which was devoted to the causes of dramatically rising prescription drug costs and ...
PBMs, middlemen that purchase drugs in bulk from manufacturers to negotiate discounts for payers, employers and consumers, have faced criticism for jacking up prices, though they maintain their job is ...
For several years now, pharmacies have faced economic challenges, from falling foot traffic to increased online competition.
The battle over pharmacy benefit manager regulation is intensifying across the U.S. With the Supreme Court declining to revisit a key PBM case and Illinois signing sweeping new restrictions into law, ...
A key Senate committee on Wednesday advanced bipartisan legislation aimed at regulating pharmacy benefit managers, the intermediaries in the prescription drug supply chain who negotiate discounts with ...
The ongoing legal dispute involving Johnson & Johnson has again thrust the topic of pharmacy benefit managers (PBMs) into the spotlight. Ann Lewandowski, a J&J employee, sued the company for ...
A new employer survey shows a growing interest in making the switch to a transparent pharmacy benefit manager. The National Alliance of Healthcare Purchaser Coalitions polled 324 public and private ...
While major pharmacy benefit management reform was stripped out of the Big Beautiful Bill, a bipartisan group of representatives has introduced legislation that takes aim at the industry. The PBM ...
WASHINGTON — A House panel passed a bipartisan bill to ban drug middlemen from charging fees based on drug list prices — the first in Congress’ raft of PBM reform efforts that would actually ban the ...
Senate Democrats on Thursday are introducing as standalone legislation a package of health policies, including changes to the pharmacy benefit manager (PBM) industry that was left out of December’s ...
The bill would require pharmacy benefit managers to submit detailed information to CMS each year that includes their interactions with the recommendation committees that decide on the drugs to be ...